Announced details
AI drug discovery, drug discovery research, disease-related gene network analysis, hypothesis generation for candidate target molecules, drug repurposing, GPCR antibody drug discovery, and evaluation of drug discovery seeds for women’s healthcare
More than 500 people attended the previous event in 2025. DDAIF has already been adopted by multiple major pharmaceutical companies.
Speakers and attendees at the conference hosted by FRONTEO. The 5 companies will present the results of drug discovery research using DDAIF. The program also mentions a strategic business alliance with 丸石製薬株式会社.
エヌビィー健康研究所, SANTEN PHARMACEUTICAL CO.,LTD., Fuji Pharma Co.,Ltd., 丸石製薬株式会社 and Meiji Seika ファルマ株式会社 are pharmaceutical or drug discovery-related companies. Shimoyama Susumu (下山進) is a nonfiction writer. Other information, including locations, capital and founding years, is not disclosed.
A total of 21 patent rights have been obtained in Japan, Europe, the United States and South Korea. Expiration dates and patent numbers are not disclosed.
Nihonbashi Life Science Hub (Chuo-ku, Tokyo)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | FRONTEO Drug Discovery AI Factory（DDAIF）, Equation-driven AI platform KIBIT |
| Counterparty | エヌビィー健康研究所, SANTEN PHARMACEUTICAL CO.,LTD., Fuji Pharma Co.,Ltd., 丸石製薬株式会社, Meiji Seika Pharma Co., Ltd., Shimoyama Susumu (下山進) |
| Counterparty overview | エヌビィー健康研究所, SANTEN PHARMACEUTICAL CO.,LTD., Fuji Pharma Co.,Ltd., 丸石製薬株式会社 and Meiji Seika ファルマ株式会社 are pharmaceutical or drug discovery-related companies. Shimoyama Susumu (下山進) is a nonfiction writer. Other information, including locations, capital and founding years, is not disclosed. |
| Relationship with the Company | Speakers and attendees at the conference hosted by FRONTEO. The 5 companies will present the results of drug discovery research using DDAIF. The program also mentions a strategic business alliance with 丸石製薬株式会社. |
| Launch date | 23 July 2026 (scheduled) |
| Applicable area | AI drug discovery, drug discovery research, disease-related gene network analysis, hypothesis generation for candidate target molecules, drug repurposing, GPCR antibody drug discovery, and evaluation of drug discovery seeds for women’s healthcare |
| Registration number and expiry date | A total of 21 patent rights have been obtained in Japan, Europe, the United States and South Korea. Expiration dates and patent numbers are not disclosed. |
| Location | Nihonbashi Life Science Hub (Chuo-ku, Tokyo) |
| Location scale | Capacity of 300 people (approximately 50 at the venue and 250 online) |
| Usage history | More than 500 people attended the previous event in 2025. DDAIF has already been adopted by multiple major pharmaceutical companies. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To share practical examples of AI drug discovery and provide a networking opportunity for pharmaceutical companies and research institutions.